$MIRM
Mirum Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000175942524000031 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $90.38M $77.88M $37.50M
YoY Change 89.37% 107.68% 114.46%
Cost Of Revenue $20.81M $20.23M $6.812M
YoY Change 103.38% 196.93% 169.89%
Gross Profit $69.57M $57.65M $30.69M
YoY Change 85.52% 87.87% 105.11%
Gross Profit Margin 76.98% 74.03% 81.83%
Selling, General & Admin $50.55M $49.21M $32.95M
YoY Change 38.37% 49.35% 57.13%
% of Gross Profit 72.65% 85.36% 107.38%
Research & Development $31.71M $32.67M $22.01M
YoY Change 21.42% 48.45% -13.46%
% of Gross Profit 45.58% 56.67% 71.73%
Depreciation & Amortization $6.055M $5.854M $1.336M
YoY Change 126.78% 338.17% 123.04%
% of Gross Profit 8.7% 10.15% 4.35%
Operating Expenses $103.1M $102.1M $61.77M
YoY Change 41.43% 65.3% 26.25%
Operating Profit -$12.68M -$24.23M -$24.27M
YoY Change -49.56% -0.17% -22.8%
Interest Expense -$117.0K -$83.00K -$99.00K
YoY Change -123.88% -16.16% -97.04%
% of Operating Profit
Other Income/Expense, Net -$1.087M $312.0K -$274.0K
YoY Change -182.22% -213.87% -121.09%
Pretax Income -$13.89M -$24.00M -$73.72M
YoY Change -40.49% -67.44% 120.12%
Income Tax $347.0K $635.0K $316.0K
% Of Pretax Income
Net Earnings -$14.24M -$24.64M -$74.04M
YoY Change -39.65% -66.72% 175.01%
Net Earnings / Revenue -15.75% -31.64% -197.45%
Basic Earnings Per Share -$0.30 -$0.52 -$1.94
Diluted Earnings Per Share -$0.30 -$0.52 -$1.94
COMMON SHARES
Basic Shares Outstanding 47.71M shares 47.13M shares 38.03M
Diluted Shares Outstanding 47.78M shares 47.24M shares 38.11M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $284.4M $278.4M $330.0M
YoY Change -7.05% -15.63% 164.06%
Cash & Equivalents $223.0M $233.2M $297.2M
Short-Term Investments $61.48M $45.13M $32.73M
Other Short-Term Assets $12.06M $8.590M $9.729M
YoY Change -3.54% -11.71% 157.52%
Inventory $21.59M $20.44M $8.509M
Prepaid Expenses
Receivables $68.53M $60.43M $35.33M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $386.6M $367.8M $383.5M
YoY Change -0.5% -4.09% 160.46%
LONG-TERM ASSETS
Property, Plant & Equipment $1.212M $1.101M $866.0K
YoY Change 54.0% 27.14% 4.09%
Goodwill
YoY Change
Intangibles $255.8M $261.8M $56.44M
YoY Change -0.98% 363.82% 22.5%
Long-Term Investments $9.321M $17.08M
YoY Change
Other Assets $5.380M $3.972M $1.153M
YoY Change 256.29% 244.49% -33.04%
Total Long-Term Assets $281.3M $292.9M $60.07M
YoY Change 7.33% 387.64% -59.95%
TOTAL ASSETS
Total Short-Term Assets $386.6M $367.8M $383.5M
Total Long-Term Assets $281.3M $292.9M $60.07M
Total Assets $667.9M $660.8M $443.6M
YoY Change 2.65% 48.96% 49.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.545M $9.842M $14.45M
YoY Change 29.53% -31.87% 77.93%
Accrued Expenses $104.7M $101.4M $42.69M
YoY Change 58.13% 137.5% 23.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $115.8M $112.3M $58.20M
YoY Change 55.03% 92.96% 28.84%
LONG-TERM LIABILITIES
Long-Term Debt $307.7M $307.2M $305.6M
YoY Change 0.54% 0.53%
Other Long-Term Liabilities $3.972M $3.972M $10.00K
YoY Change 56642.86% 39620.0% -99.76%
Total Long-Term Liabilities $3.972M $3.972M $10.00K
YoY Change 56642.86% 39620.0% -99.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $115.8M $112.3M $58.20M
Total Long-Term Liabilities $3.972M $3.972M $10.00K
Total Liabilities $435.9M $431.8M $365.0M
YoY Change 14.23% 18.3% 95.65%
SHAREHOLDERS EQUITY
Retained Earnings -$620.4M -$606.2M -$497.0M
YoY Change 19.17% 21.97% 54.97%
Common Stock $851.5M $835.6M $575.5M
YoY Change 7.63% 45.19% 33.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $232.0M $229.0M $78.61M
YoY Change
Total Liabilities & Shareholders Equity $667.9M $660.8M $443.6M
YoY Change 2.65% 48.96% 49.24%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$14.24M -$24.64M -$74.04M
YoY Change -39.65% -66.72% 175.01%
Depreciation, Depletion And Amortization $6.055M $5.854M $1.336M
YoY Change 126.78% 338.17% 123.04%
Cash From Operating Activities $3.984M -$3.803M -$2.331M
YoY Change -121.87% 63.15% -88.44%
INVESTING ACTIVITIES
Capital Expenditures $10.18M $10.78M $15.07M
YoY Change -28.46% -88735.29%
Acquisitions
YoY Change
Other Investing Activities -$7.855M -$61.94M $50.62M
YoY Change -95.7% -222.37% 111.0%
Cash From Investing Activities -$18.04M -$72.72M $35.55M
YoY Change -90.13% -304.57% 48.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $305.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.863M 7.291M 114.7M
YoY Change -98.13% -93.64% 2086.56%
NET CHANGE
Cash From Operating Activities 3.984M -3.803M -2.331M
Cash From Investing Activities -18.04M -72.72M 35.55M
Cash From Financing Activities 3.863M 7.291M 114.7M
Net Change In Cash -10.19M -69.23M 147.9M
YoY Change -265.67% -146.8% 1535.41%
FREE CASH FLOW
Cash From Operating Activities $3.984M -$3.803M -$2.331M
Capital Expenditures $10.18M $10.78M $15.07M
Free Cash Flow -$6.197M -$14.58M -$17.40M
YoY Change -65.99% -16.19% -13.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.75
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47235080 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47235080 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38107334 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38107334 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
142037000 usd
CY2023Q1 mirm Stock Issued During Period Value Contingent Milestone Achievement
StockIssuedDuringPeriodValueContingentMilestoneAchievement
4292000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8728000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30130000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
353000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
141150000 usd
CY2023Q2 mirm Stock Issued During Period Value Indemnification Holdback Liability
StockIssuedDuringPeriodValueIndemnificationHoldbackLiability
896000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8565000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-74038000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-60000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
78610000 usd
us-gaap Profit Loss
ProfitLoss
-49917000 usd
us-gaap Profit Loss
ProfitLoss
-104168000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23285000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
16918000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11518000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2673000 usd
mirm Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity
InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity
-1676000 usd
mirm Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity
InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity
-665000 usd
mirm Cost Recognized On Sale Of Acquired Inventory
CostRecognizedOnSaleOfAcquiredInventory
4566000 usd
mirm Cost Recognized On Sale Of Acquired Inventory
CostRecognizedOnSaleOfAcquiredInventory
0 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
821000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
307000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-49076000 usd
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
0 usd
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
5060000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2089000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
mirm Non Cash Lease Expense
NonCashLeaseExpense
585000 usd
mirm Non Cash Lease Expense
NonCashLeaseExpense
290000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
795000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7538000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11332000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2345000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
782000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6615000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1767000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
88000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-229000 usd
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
18221000 usd
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
7964000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-462000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-443000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11409000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36105000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
61938000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
27329000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
120000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
792000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
15000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72730000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77562000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14480000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
305304000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8496000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3487000 usd
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
0 usd
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-195577000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8496000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127694000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52831000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
169225000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
286326000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
128003000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
233495000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
297228000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
602000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
527000 usd
us-gaap Interest Paid Net
InterestPaidNet
6325000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
339000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
10000000 usd
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
0 usd
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
-3509000 usd
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1467000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8896000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
473000 usd
mirm Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification
RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification
723000 usd
mirm Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification
RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification
0 usd
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
694000 usd
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
375000 usd
mirm Stock Issued During Period Value Contingent Milestone Achievement
StockIssuedDuringPeriodValueContingentMilestoneAchievement
0 usd
mirm Stock Issued During Period Value Contingent Milestone Achievement
StockIssuedDuringPeriodValueContingentMilestoneAchievement
5188000 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
mirm Number Of Approved Medicines
NumberOfApprovedMedicines
3 medicine
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-606200000 usd
CY2024Q2 us-gaap Investments And Cash
InvestmentsAndCash
295400000 usd
CY2024Q2 us-gaap Investments And Cash
InvestmentsAndCash
295400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, bank failures, high interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></div>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
233245000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297228000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
250000 usd
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
0 usd
mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
mirm Fair Value Of Its Investments Related To Credit Loss
FairValueOfItsInvestmentsRelatedToCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2024Q2 mirm Purchase Commitments
PurchaseCommitments
5900000 usd
CY2023Q4 mirm Purchase Commitments
PurchaseCommitments
5200000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
286590000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24822000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261768000 usd
CY2024Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y6M
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
266590000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13665000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
252925000 usd
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y3M18D
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11200000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2500000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
11951000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23903000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23795000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23579000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
23579000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
154961000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261768000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77875000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37497000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147097000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69095000 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
400000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2100000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22173813 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20634345 shares
CY2024Q2 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
270809000 usd
CY2024Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000 usd
CY2024Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000 usd
CY2024Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
270816000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
208615000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
45126000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
17075000 usd
CY2024Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
270816000 usd
CY2023Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
278116000 usd
CY2023Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
278116000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
278116000 usd
CY2023Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
278116000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
45126000 usd
CY2024Q2 mirm Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One And Two
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneAndTwo
17075000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
62201000 usd
CY2024Q2 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
CY2023Q2 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2790000 usd
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2998000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
11593000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9873000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6055000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9441000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
20438000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
22312000 usd
CY2024Q2 mirm Accrued Sales Deductions Current
AccruedSalesDeductionsCurrent
37249000 usd
CY2023Q4 mirm Accrued Sales Deductions Current
AccruedSalesDeductionsCurrent
23650000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16775000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20939000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
13130000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7941000 usd
CY2024Q2 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
8331000 usd
CY2023Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
9922000 usd
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7420000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6716000 usd
CY2024Q2 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6381000 usd
CY2023Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
7268000 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2108000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2108000 usd
CY2024Q2 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
10000000 usd
CY2023Q4 mirm Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
0 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
101394000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
78544000 usd
CY2023Q2 mirm Stock Issued During Period Shares Indemnification Holdback Liability
StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability
31631 shares
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600 sqft
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
633000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2207000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2257000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2321000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2330000 usd
CY2024Q2 mirm Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1551000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11299000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1983000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9316000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0 usd
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26099854 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24145170 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11835000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8357000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23285000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16918000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
500000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
200000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
700000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001759425-24-000031-index-headers.html Edgar Link pending
0001759425-24-000031-index.html Edgar Link pending
0001759425-24-000031.txt Edgar Link pending
0001759425-24-000031-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-10qq224xexx101.htm Edgar Link pending
mirm-10qq224xexx311.htm Edgar Link pending
mirm-10qq224xexx312.htm Edgar Link pending
mirm-10qq224xexx321.htm Edgar Link pending
mirm-10qq224xexx322.htm Edgar Link pending
mirm-20240630.htm Edgar Link pending
mirm-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
mirm-20240630_cal.xml Edgar Link unprocessable
mirm-20240630_def.xml Edgar Link unprocessable
mirm-20240630_lab.xml Edgar Link unprocessable
mirm-20240630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mirm-20240630_pre.xml Edgar Link unprocessable